Brand Name: Opdivo
Opdivo is a medicinal drug prescribed via way of means of Israeli docs for the remedy of diseases such as:
• Melanoma – In instances in which the sickness has unfolded to different organs and can’t be eliminated surgically or for the reason of adjuvant remedy (prevention).
• Metastatic non-small mobileular lung carcinoma (NSCL) – in instances in which the sickness advanced for the duration of or after chemotherapy remedy.
OPDIVO suggests 50% longer median standard survival vs. Chemotherapy* (9.2 vs. 6.zero months) in sufferers with NSCL, in step with the take a look at that blanketed PD-L1 Expressers and Non-Expressers.
• Hodgkin’s lymphoma after antilogous stem mobileular transplantation.
Proven in medical take a look at:– Tumors cut back or disappeared absolutely in 69% (179 of 258 sufferers);
– Tumors cut back (partial response) in 55% (142 of 258);
– Tumors disappeared absolutely (whole response) in 14% (37 of 258). The medical trials are being persisted. Nivolumab, bought below the emblem call Opdivo, is a medicine used to deal with some of kinds of most cancers.
This consists of cancer, lung most cancers, renal mobileular carcinoma, Hodgkin lymphoma, head and neck most cancers, colon most cancers, and liver most cancers. It is utilized by gradual injection right into a vein.[ Nivolumab became accepted for clinical use with inside the United States in 2014. It is at the World Health Organization’s List of Essential Medicines. It is made the usage of Chinese hamster ovary cells.
Treatment with OPDIVO
OPDIVO is used to deal with superior pores and skin most cancers (unrespectable or metastatic cancer). OPDIVO is likewise used to deal with pores and skin most cancers (cancer) after surgical elimination of the most cancers. OPDIVO is used to deal with a sort of lung most cancers (superior squalors and non squalors non-small mobileular lung most cancers) , a sort of kidney most cancers (clean mobileular renal mobileular carcinoma) , a sort of head and neck most cancers (squalors mobileular most cancers of the pinnacle and neck), a sort of blood most cancers referred to as classical Hodgkin lymphoma, a sort of bladder most cancers (urothelial carcinoma), a sort of liver most cancers (hepatocellular carcinoma) and a sort of meals pipe most cancers (esophageal most cancers), in case your most cancers has now no longer responded, or if it has stopped responding, to in advance
Treatment with OPDIVO in mixture with ipilimumab OPDIVO in mixture with ipilimumab is used to deal with superior cancer in adults and a sort of superior kidney most cancers (renal mobileular carcinoma) and malignant pleural mesothelioma (a sort of most cancers that influences the liner of the lung)
INDICATIONS AND USAGE
OPDIVO is a programmed loss of life receptor-1 (PD-1) blockading antibody indicated for the remedy of: Melanoma, Non-Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Renal Cell Carcinoma (RCC) Classical Hodgkin Lymphoma (CHL), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Esophageal Squamous Cell Carcinoma (ESCC).
DOSAGE FORMS & STRENGTHS
40 mg/four mL, a 100mg/10 mL, and 240 mg/24 mL answer in a single-dose vial. 3mg/kg via way of means of intravenous infusion over 60 mins each 2 weeks.
Treatment must be persisted as lengthy as medical advantage is determined or till remedy is now no longer tolerated via way of means of the affected person. Dosing postpone or discontinuation can be required primarily based totally on character protection and tolerability and further info are supplied with inside the précis of product characteristics.
1 Treatment have to be initiated and supervised via way of means of physicians skilled with inside the remedy of most cancers. Patients dealt with nivolumab have to accept the affected person alert card and be knowledgeable approximately the risks of nivolumab.
1 ADVICE: following a complete submission assessed below the give up of existence process nivolumab (Opdivo® ) is common to be used inside NHS Scotland. Indication below review:
Treatment of domestically superior or metastatic squamous non-small mobileular lung most cancers (NSCLC) after previous chemotherapy in adults. Nivolumab, in comparison with a popular second-line chemotherapy, substantially improved standard survival in sufferers with domestically superior or metastatic squamous NSCLC who had acquired previous remedy which include platinum-primarily based totally doublet chemotherapy.
This recommendation takes account of perspectives from a Patient and Clinician Engagement (PACE) meeting.
This SMC recommendation takes account of the advantages of a Patient Access Scheme (PAS) that improves the cost-effectiveness of nivolumab. This recommendation is contingent upon the persevering with availability of the PAS in NHS Scotland or a listing charge this is equal or lower. Side Effects:
Important matters to don’t forget approximately the facet consequences of nivolumab:
• Most humans do now no longer revel in all the facet consequences listed
• Side consequences are frequently predictable in phrases in their onset and duration.
• Side consequences are nearly usually reversible and could leave after remedy is whole.
• There are many alternatives to assist limit or save you facet consequences.
• There isn’t any any dating among the presence or severity of facet consequences and the effectiveness of the medicine.
The following facet consequences are not unusual place (going on in extra than 30%) for sufferers taking nivolumab:
• Lymphocytopenia (low white blood cells)
• Low sodium
• Shortness of breath
• Musculoskeletal pain
• Decreased appetite
• Cough these facet consequences are much less not unusual place facet consequences (going on in approximately 10-29%) of sufferers receiving nivolumab:
• Low potassium
• Low magnesium
• High calcium
• High potassium
• Low calcium
• Abdominal pain
• Increased serum AST